Sunday, March 29, 2015

Ohr Pharma stock tumbles on Phase 2 trial results

Ohr Pharma stock tumbles on Phase 2 trial results

March 27, 2015 by · Leave a Comment 

Tweet Ohr Pharmaceutical’s (NASDAQ:OHRP) experimental eye drug failed the main goal as a combination therapy in a mid-stage study, sending the company’s shares plunging 67% in the afternoon session on Friday. The study tested the eye-drop solution, OHR-102, in combination with Roche’s injectable eye drug, Lucentis, in patients with the wet age-related macular degeneration (AMD), […]

Atara appoints Eric Dobmeier to board

Atara appoints Eric Dobmeier to board

March 27, 2015 by · Leave a Comment 

Tweet Atara Biotherapeutics (NASDAQ:ATRA) has appointed Eric Dobmeier, COO of Seattle Genetics, to the board. Mr. Dobmeier joined Seattle Genetics in March 2002 and has served in positions of increasing responsibility since then, most recently as chief business officer from May 2007 to June 2011. Isaac Ciechanover, CEO of Atara, said Mr. Dobmeier’s vast experience […]

Amarantus to start Phase 2b with eltoprazine in PD

Amarantus to start Phase 2b with eltoprazine in PD

March 26, 2015 by · Leave a Comment 

Tweet Amarantus BioScience Holdings (OTCQB:AMBS) has an active IND application with the neurology division of the FDA to start a Phase 2b program of eltoprazine for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). The company expects to initiate patient enrollment and dosing in a 60-subject clinical study in individuals with PD in the second […]

Transition posts positive AME, renal clearance studies with ELND005

Transition posts positive AME, renal clearance studies with ELND005

March 26, 2015 by · Leave a Comment 

Tweet Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) has reported positive results from two Phase 1 clinical studies of its neuropsychiatric drug candidate ELND005. The studies were an absorption metabolism excretion (AME) study and a renal clearance study. They are specialized clinical pharmacology trials that are required by the FDA for the approval of most drugs in development. […]

Roth starts Argos Therapeutics at buy

Roth starts Argos Therapeutics at buy

March 26, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Argos Therapeutics (NASDAQ:ARGS) with a “buy” rating and $21 price target, saying the company has the potential to be one of the leaders in cancer immunotherapy. The stock closed at $8.92 on Wednesday. Argos’ proprietary technology platform, Arcelis, is based on the work of Nobel Prize-winning co-founder, […]

CombiMatrix selects Cryoport as logistics partner

CombiMatrix selects Cryoport as logistics partner

March 24, 2015 by · Leave a Comment 

Tweet CombiMatrix (NASDAQ:CBMX) has selected Cryoport (OTCBB:CYRX) as its cryogenic logistics partner for the distribution of its new CombiPGS genetic screening test. Cryoport is the leader in global cryogenic logistics for frozen eggs, embryos, and sperm, serving the reproductive medicine market. Cryoport works with more than 260 clinics in the U.S. in addition to clinics […]

Relmada cleared for PK study with BuTab

Relmada cleared for PK study with BuTab

March 24, 2015 by · Leave a Comment 

Tweet Relmada Therapeutics (OTCQB:RLMD) has received a No Objection Letter from Health Canada to conduct the first pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (BuTab, REL-1028) being developed for the treatment of both chronic pain and opioid dependence. “If we can demonstrate that oral BuTab compares favorably with currently marketed sublingual formulations of […]

Actinium opens enrollment of final cohort in Phase I/II AML trial

Actinium opens enrollment of final cohort in Phase I/II AML trial

March 24, 2015 by · Leave a Comment 

Tweet Actinium Pharmaceuticals (NYSE MKT:ATNM) is moving forward with enrollment and treatment of additional patients in its clinical trial for acute myeloid leukemia (AML) in patients over the age of 60. Actinium will proceed with patient screening and enrollment for the fourth cohort, who, in keeping with trial protocol, will be injected with two doses, […]

Leerink starts Neovasc at outperform

Leerink starts Neovasc at outperform

March 20, 2015 by · Leave a Comment 

Tweet Leerink Partners has launched coverage of Neovasc (NASDAQ:NVCN) with an “outperform” rating and $25 price target. The stock closed at $9.20 on Thursday. “Though still early in development, we believe Neovasc is on the verge of tapping into the dramatically large and potentially high growth transcatheter mitral valve replacement (TMVR) market with its Tiara […]

HCW ups La Jolla Pharma price target to $29

HCW ups La Jolla Pharma price target to $29

March 20, 2015 by · Leave a Comment 

Tweet H.C. Wainwright has raised its price target on La Jolla Pharmaceutical (NASDAQ:LJPC) to $29 from $20. The stock closed at $23.09 on Thursday. “Based on the clinical profile to date, the portfolio of diverse assets, the potential to secure an ex-U.S. partnership, and a cash position of $41.8-million (pro forma), we believe La Jolla […]

Next Page »

Email Newsletters with Constant Contact
Google+